Yeast-based functional genomics and proteomics technologies developed
INTRODUCTION
Although the fields of functional genomics and proteomics are relatively young, they have benefited greatly from analysis of the baker's yeast Saccharomyces cerevisiae (1) . This single-celled fungus has long been an effective eukaryotic model system for understanding basic cellular processes due to its ease of manipulation and genetic tractability (2, 3) . Yeast has a short life cycle of 90 min, it is inexpensive to maintain and grow, it is stable in both the haploid and diploid state, and it is classified as a generally recognized as safe (GRAS) microorganism. Its haploid genome is of relatively low complexity (1.2 × 10 7 bp) and is packaged into 16 well-characterized chromosomes (4) . Furthermore, yeast was the first eukaryotic genome for which genome sequence was reported (5) , and its 6466 open reading frames (ORFs) (6, 7) exist in a readily usable form (8) . Annotated information on the function of these ORFs and their corresponding protein products is available through several databases, including the Saccharomyces Genome Database (SGD; www.yeastgenome. org), the Yeast Protein Database (YPD; www.proteome.com), the Munich Information Center for Protein Sequences (MIPS) Comprehensive Yeast Genome Database (CYGD; mips. gsf.de/genre/proj/yeast/index.jsp), and the Yeast Resource Center (depts. washington.edu/~yeastrc). In addition, a big advantage of yeast compared with other eukaryotic model organisms is its relatively high rate of recombination between homologous DNA sequences that allows precise insertion of DNA sequences at specific locations within the yeast genome. This phenomenon enables a simple gene knockout technique to be performed in yeast using a PCR-mediated approach and the integration of a selectable marker and/or a mutant allele (9) . Similar approaches can be used to introduce regulated promoters upstream of a given ORF (10) or to introduce different epitope tags (11) .
Yeast has also been successfully used for many years as a model for mammalian diseases and pathways. In fact, the cellular target of rapamycin, an immunosuppressant used as an antirejection drug in tissue transplants, was first discovered in yeast and then subsequently verified in humans (12) . Along these lines, yeast is a valuable predictor of human gene function; at least 31% of proteins encoded by yeast genes have human homologs, and conversely, nearly 50% of human genes implicated in heritable diseases have yeast homologs (13) . In summary, yeast has definitively improved our understanding of fundamental cellular processes and metabolic pathways in humans and has facilitated the molecular analysis of many disease genes.
In this review, we give a comprehensive overview of the most important yeast-based functional genomic and proteomic technologies that are advancing the utility of yeast as a model organism in modern biomolecular research. These approaches include utilization of the yeast deletion strain collection, large-scale determination of protein localization in vivo, synthetic genetic arrays, variations of the yeast two-hybrid system, protein microarrays, and tandem affinity purification (TAP)-tagging.
In model organisms, the function of every known gene or predicted ORF can be analyzed by assessing growth defects or other phenotypes when the gene or ORF is deleted or the gene product is inactivated. Systematic generation of null or loss of function mutants and subsequent phenotypic analysis will therefore allow the functional categorization of all genes. Among eukaryotic model organisms, the yeast S. cerevisiae has been most extensively studied by systematic and genome-wide approaches.
Undoubtedly, one of the most important milestones for yeast functional genomics was the construction of a complete set of deletion mutants (14, 15) . This collection of null mutants allowed for the first time a comprehensive and parallel analysis of phenotypes in a model organism. In its final version, 5916 out of the originally annotated approximately 6200 yeast ORFs were successfully deleted for the construction of a heterozygous diploid collection that contains deletions in both essential and nonessential genes (14) . In addition, sets of approximately 4800 nonessential deletions have been generated independently as haploid MATa and MATα strains or as homozygous diploids. The collections are available from Research Genetics (ResGen) (www.resgen.com/products/ YEASTD.php3) or the Euroscarf consortium (web.uni-frankfurt.de/fb15/ mikro/euroscarf/col_index.html).
Since the deletion collection was first described (15) , numerous yeast laboratories have tested drug sensitivities and fitness defects of the mutant strains. Collection strains that are sensitive toward the cytotoxic or growth inhibitory effects of a specific compound can simply be identified by their absence or slow growth on medium containing the chemical. Plating assays have been used to test the homozygous diploid and haploid collections for sensitivities toward individual chemicals and different growth conditions (for some recent examples see . In one extensive series of experiments, haploid gene deletion mutants were screened for hypersensitivities toward 12 inhibitory compounds (21) . Drugs were selected that inhibited a set of different cellular pathways. These included, among others, (i) the microtubule-inhibitor benomyl; (ii) the immunosuppressants FK506 and cyclosporine that target calcineurinB; (iii) the ribonucleotide reductase inhibitor hydroxyurea; (iv) wortmannin, an inhibitor of phosphatidylkinase signaling; and (v) fluconazole, an antifungal compound that affects ergosterol biosynthesis. The screens identified a set of multidrug resistance genes that are required for resistance toward different compounds with diverse modes of action (i.e., PDR5, SNQ1, and YOR1). Filtering of these genes from the data sets revealed specific information about the pathways that are required to buffer the effects of the individual compounds. Increased compound sensitivities of individual mutant cells can be integrated into a chemical-genetic interaction profile. The different classes of mutant strains that are affected in presence of a compound generate distinct interaction profiles. Notably, chemical interaction profiling is also useful when a compound is not directed against a specific protein target. In this case, the interaction profile highlights primary pathways or cellular functions that are affected by the drug. Large pools of heterozygous or homozygous yeast deletion strains are grown in the presence or absence of a drug (pink squares). In the collection, each gene deletion (red and blue) is flanked by two sequences that contain unique barcodes (up-tag and down-tag). After DNA extraction, the barcodes are amplified using primers from conserved sequences in the tags and hybridized to barcode microarrays. Relative abundance of each bar-coded PCR product is compared between arrays from treated or untreated samples. Absence of a hybridization signal in the treated sample reveals sensitivity of the corresponding deletion strain (red deletion) to the drug. Note that this scheme depicts the hybridization of treated and untreated samples to different arrays.
As an efficient method to monitor fitness defects, Ron Davis and coworkers established a protocol for competitive growth in large pools of deletion strains (14, 15) . This method allows massive parallel analysis of individual strains under different growth conditions in relatively small volumes of liquid culture (Figure 1) . Growing a large pool of deletion strains in the presence of a specific bioactive compound, sensitive deletion strains are outcompeted by thousands of unaffected strains in the pool. A sophisticated system of unique DNA barcodes allows an unambiguous identification and quantification of individual mutants in the mixed population. Tags that contain barcode sequences are engineered into the 5′ and 3′ ends of each deletion cassette. Upon amplification of the tags, the presence or absence of each deletion strain is assessed by hybridization to barcode microarrays. Mutants that are sensitive to a specific drug are not detected by their corresponding barcodes, whereas barcode signals from unaffected or resistant strains are represented on the array. Strains that are slow growing under normal conditions and not specifically affected by the drug drop out in the untreated control sample and can therefore be recognized. Competitive growth experiments are better for the detection of weak sensitivities than direct plating assays. Furthermore, competitive growth requires only small amounts of liquid culture to screen the entire yeast collection and is therefore more cost-effective than direct plating assays when expensive compounds are tested.
In the first release of the yeast deletion collection, the growth phenotypes of more than 500 deletion strains were assayed in parallel (15) . Then, in the final assembly of the collection, Ron Davis and coworkers tested the entire homozygous deletion pool for changes under different growth conditions including pH, high salt, sorbitol, minimal media, galactose, and treatment with the antifungal compound nystatin (14) . This work identified previously unknown genes that are required for growth under each tested condition, including 10 new genes that are required for growth in galactose. About 15% of the homozygous deletions were found to have a slow growth phenotype at 30°C in rich medium. Many of these genes encode ribosomal proteins and proteins involved in mitochondrial function and respiration. Mitochondrial genes were the focus of another experiment, in which the heterozygous and homozygous deletion collections were screened for growth on nonfermentable carbon sources (22) . In total, 466 gene deletions were found to impair mitochondrial respiration, 201 of which encoded proteins with known mitochondrial localization or function. Human orthologs for yeast genes that have deletion phenotypes on nonfermentable carbon sources were then identified as candidate genes for human mitochondrial disease. This example shows how the conservation of cellular pathways among eukaryotes supports the use of yeast genomics to better understand these pathways in human.
Many compounds that are used in cancer therapy mediate their effect through the induction of DNA damage. Notably, most of the currently used cancer therapeutics were originally introduced without their exact mode of action and the affected cellular pathways being defined. This includes, for example, the DNA cross-linking agent cisplatin, which is an effective chemotherapeutic for most germline testicular tumors (23) . To understand the genetic requirements for drug sensitivity and resistance, an important concept developed by Lee Hartwell and Stephen Friend was to screen chemicals for toxicity in yeast cells that have metabolic defects similar to those frequently found in human cancers (24) . Indeed, the high-throughput screening of the yeast deletion collection was successful in determining interaction profiles for different compounds that introduce structural DNA damage, including known anticancer drugs. Compounds and environmental agents that were screened include, for example, methyl-methanesulfonate and hydroxyurea (17) , bleomycin (16) , cisplatin (18) , ionizing radiation (25) , and UV radiation (26) . These screens mainly uncovered genes that are involved in DNA repair, checkpoints, DNA recombination, and DNA replication. In the last example (26), mutations in LSM1 and YAF9, which have human orthologs associated with cancer, conferred UV sensitivity. Recently, sensitivity in approximately 4700 homozygous deletion strains toward the induction of DNA damage was measured in a parallel analysis with 12 different compounds (27) . A particular emphasis was placed on chemicals that induce cross-links between complementary DNA strands (e.g., the structurally related drugs cisplatin, oxaliplatin, and carboplatin). Clustering of the data showed the importance of nucleotide excision repair, but also of homologous recombination and postreplication repair in the cellular response toward these agents. It also highlighted a distinct profile for carboplatin, reflecting a different mode for damage response or reactivity of this drug. Furthermore, the genes MPH1, SHU1, SHU2, CSM2, and PSY3 were defined as a separate epistasis group that constitutes a separate branch in DNA repair by homologous recombination.
While most of the screenings discussed in this review simply identified sensitivities and resistances of different mutant strains to drugs by testing growth and viability, a number of studies used the yeast deletion collection to study more complex phenotypes. Recent examples include two studies by the labs of Brian Kennedy and Stan Fields that used the yeast deletion collection to find factors that affect aging in yeast (28, 29) . In the first study, replicative life span (RLS), the measure of the number of cell divisions that can be performed by an individual mother cell, was determined for 564 deletion strains (28) . Ten gene deletions were found to increase lifespan, and six of these genes were involved in nutrient response, specifically the target of rapamycin (TOR) and the Sch9 pathways. In the second study, chronological life span (CLS), a measure of the time nondividing cells can remain viable in liquid media, was assessed for the entire collection of homozygous diploid deletions (29) . Mutations deficient in nutrient response and TOR signaling were also the most prominent in prolonging CLS. Consequently, removal of preferred yeast nitrogen sources glutamine and arginine, but also direct inhibition of TOR signaling and inhibition of glutamine synthetase, led to an increase in CLS.
Drug-Induced Haploinsufficiency Screens
The competitive growth approach is especially useful for the parallel analysis of drug-induced haploinsufficiency in the heterozygous deletion collection (30) (31) (32) . A cell is haploinsufficient when lowering the dosage of a gene encoding a potential drug target from two copies to one copy confers hypersensitivity to the drug (Figure 2A ). The readouts from haploinsufficiency screens are distinct from chemical-genetic screens with complete homozygous null mutations. Whereas screens with homozygous deletions highlight genes that are important for survival in the presence of a compound, the haploinsufficency approach relies on a dosage effect and is expected to reveal the primary target for the small molecule. Furthermore, haploinsufficiency allows the analysis of fitness defects in essential genes, which is not possible if homozygous diploid or haploid strains were used. On the other hand, the haploinsufficiency approach is limited when the drug target is not a protein (e.g., DNA damage) or when the direct effects of the drug are masked by a redundant protein function. Furthermore, growth deficiencies may not be detected in heterozygous deletion mutants where the relevant protein remains in excess of minimum levels ( Figure 2B ) (22) .
An initial study used a small set of 233 yeast deletions to establish the feasibility of the haploinsufficency approach and the experimental procedures (30) . More recently, two independent studies tested different compounds that are relevant for human health and agriculture (31, 32) . The first study by Lum et al. tested 78 compounds on a set of 3503 heterozygous yeast deletions (31) . For a majority of the 20 compounds with characterized functions that were included in the study, the correct targets and other components of the known target pathways were identified. Six of the correctly identified targets are involved in the ergosterol biosynthesis pathway, which is sensitive to various compounds (e.g., lovostatin and antifungal azoles). Furthermore, the study also revealed a number of potential new drug targets. For example, the drug molsidomine, a potent vasodilator used in the treatment of angina (33) was found to be an inhibitor of the Erg7p lanosterol synthase. Heterozygotes for the deletion of ERG7 showed hypersensitivity to molsidomine, and the purified lanosterol synthase was inhibited in vitro by SIN-1, the first metabolic derivative of molsidomine. This result revealed therefore the likely molecular mechanism for the cholesterol-lowering properties of this drug in rats and humans. However, for some established compounds, no targets were identified, or the results from the screens were unexpected. The antimetabolite 5-flourouracil (5FU) is one of the most widely used chemotherapeutics for the treatment of solid tumors. Although 5FU was thought to inhibit thymidylate synthase (34) , the deletion mutant of thymidylate synthase was not identified in the haploinsufficiency profile. However, a large set of genes involved in ribosomal RNA processing was sensitive to 5FU treatment. Subsequent characterization of ribosomal RNA (rRNA) intermediates by Lum et al. suggested that 5FU disrupts rRNA processing by the exosome complex (31) .
The second study by Giaever et al. (32) examined the complete collection of 5916 heterozygous deletion strains for sensitivity toward a set of 10 diverse compounds. Known interactions were supported for the anticancer drug methotrexate (DFR1), antifungal azoles (ERG11), and statin compounds that affect the HMG-CoA reductase (HMG1). Giaever et al. also identified the haploinsufficiency of rRNA processing mutants in the presence of 5FU, but attributed this phenotype to misincorporation of 5FU into RNA (32) . Most interesting in this study, alverine citrate, a muscle relaxant, fenpropimorph, an antifungal, and dyclonine, an anesthetic, had similar profiles in the haploinsufficiency screens. Indeed, these three therapeutically distinct compounds were then found to share a similar chemical structure. This suggests that comprehensive haploinsufficiency profiling will possibly reveal unexpected relationships between activity and structure for other therapeutic compounds.
Phenotypic analysis of the yeast mutant collections revealed invaluable clues about chemical genetic interactions and an overview of metabolic pathways that is not easily achieved in higher eukaryotes. The fact that many human disease-associated genes have conserved yeast counterparts (e.g., in DNA damage response) makes chemical genomics in yeast a powerful tool for testing relevant bioactive compounds (13) . Unfortunately, many Haploinsufficiency cannot be observed when the potential drug target is in excess even when one gene copy is deleted. (35) (36) (37) . RNAi libraries can also be generated to silence gene expression in mammalian cells (38) . Hence, the parallel analysis of cell cultures that have the expression of different genes compromised by RNAi could allow rapid assessment of drug effects in more complex cells.
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Synthetic Genetic Arrays and Genome-Wide Synthetic Lethal Screens
The synthetic genetic array (SGA) methodology ( Figure 3A) is an important application of the yeast deletion collection that allowed, for the first time, the systematic construction of double mutants and the subsequent analysis of growth phenotypes (39, 40) . A query strain with a specific mutation (deletion or conditional allele) is mated with the entire haploid collection of the opposite mating type. A tight selection procedure allows only haploids, but not diploids, to germinate after sporulation. After the final selection step, phenotypes (e.g., sickness or lethality) are scored in double mutants containing both selective markers from the query strain and the deletion collection. Robotic high-density format pinning and replica printing of the deletion strains ensures high reproducibility and efficiency of the procedure. Results from the SGA analysis are then verified by tetrad analysis or by a fast and more efficient growth analysis after random sporulation (for a more detailed description see Reference 41) .
SGA is especially good at showing functional redundancies that lead to synthetic lethal (SL) or synthetic sick (SS) interactions when two genes are compromised that have no or a lesser effect on viability by themselves. SL or SS is known to occur when two mutations compromise redundant pathways that are by themselves nonessential ( Figure 3B ). Alternatively, SL or SS interactions can be observed when two mutations impinge on the same essential pathway or when an essential protein complex is destabilized. Previously, screens for synthetic lethality were based on plasmid loss in colony-sectoring assays (42) . These approaches were hampered by practical limitations, and only a handful of synthetic interactions were discovered in a single screen. Therefore, with traditional synthetic lethal screens, the number of synthetic interactions found for a gene was always far from saturation. A haploid strain containing the query mutation (red) is combined with the arrayed deletion collection of the opposite mating type (blue). After mating, diploids are selected and sporulated to yield the haploid progeny. For the crucial selection step against diploids, the query strain contains a special construct that allows for the selection of haploids from one mating type. The use of additional resistance markers (e.g., canavanine resistance, can1Δ) makes the process more stringent, specifically allowing additional selection against diploids that became homozygous by gene conversion. The final selection for haploid double mutants is done with the antibiotic resistances from the deletion collection and the query strain. In case of a synthetic sick or lethal interaction, the double mutant is compromised or cannot be recovered. (B) The principle of synthetic lethality. Inactivation (deletion) of two genes (red and blue) in redundant pathways leads to loss of viability, whereas inactivation of either one gene has no effect. (C) Drug-induced inhibition of growth in haploid or homozygous diploid deletion strains (chemical-genetic interaction). A protein product of a gene (red circles) is inactivated by treatment with a drug (pink squares). The protein product of a second gene (blue circles) is by itself not essential but prevents loss of viability in the presence of the drug. Deletion of the second gene leads therefore to hypersensitivity to a dose of the drug that that is not lethal in a wild-type cell.
REVIEW 4000 interactions (40) . The inference from clustered SGA data allows the assignment of functions to previously unknown genes (40) . For example, the clustering of synthetic interactions and follow-up studies revealed that Csm3p cooperates with Mrc1p and Tof1p in the DNA replication checkpoint. Furthermore, focused SGA screens have been applied to address specific questions in several research areas, including polarized growth (43) , sister chromatid cohesion (44, 45) , DNA replication (46) (47) (48) , chitin synthesis for the cell wall (49) , and transcription (50) . The SGA screens that were done so far detected only a fraction of the synthetic interactions that are presumed to occur in a yeast cell. However, the massive increase in the number of genetic interaction data will eventually allow a comprehensive overview of the genetic interaction network.
Approximately 20% (or 1105) of yeast genes are essential and therefore not represented in the haploid deletion collection and not accessible for SGA. Recently, methods have been developed that make essential genes accessible for high-throughput analysis. In one approach, a collection of promoterreplacement alleles was constructed for over two-thirds of all essential yeast genes (10) . In these strains, an activator binding sequence is integrated into the promoters of the candidate genes conferring high expression levels to the protein in the presence of the activator (tetA). Inhibition of tetA by the chemical doxycycline leads to a shutoff of target gene expression coming close to the effect that would be expected for a deletion of the essential gene. Upon addition of the inhibitor and depletion of mRNA levels, the strains in the collection were analyzed for cellular morphology, size, drug sensitivity, and mRNA expression profiles. Importantly, the promoterreplacement collection is also suitable for SGA analysis. More recently, 30 different temperature-sensitive mutants or deletions in nonessential genes with defects in diverse cellular processes were crossed with an array containing 575 promoter-replacement alleles in essential genes (51) . The resulting synthetic interaction network showed a higher number of synthetic lethal interactions for essential genes, compared with nonessential genes. The promoter replacement system was also used to assign functions to previously uncharacterized genes. This included the identification of Pga1p as a new factor that has a role in protein sorting or modification in the endoplasmic reticulum (51) . Finally, an effort is currently underway to generate a comprehensive collection of temperature-sensitive mutations in essential genes as a resource for future SGA analysis (C. Boone, personal communication).
A modified version of SGA has been developed that allows quantitation of aggravating or alleviating interactions between pairs of genes with categorized functions by using epistatic miniarray profiles (eMAPs) (52) . This eMAP strategy has been successfully used for cellular trafficking and secretory processes. The same study also introduced destabilization of mRNA by disruption of the 3′ untranslated region (UTR) sequences as a method to study phenotypes that arise by reduction in the level of essential gene expression. An alternative methodology to assess synthetic interaction between genes is synthetic lethality analysis by microarray (SLAM), which combines the principles of SGA and competitive growth. The query genes are integrated into the haploid deletion (SLAM) by transformation (53) . To assess the quantitative strength of each interaction, barcodes are then used to detect the relative abundance of individual deletions on microarrays. SLAM was successfully used to analyze functional relationships between helicases that are involved in chromosome metabolism. Recently, a modified version of SLAM has been developed (dSLAM), in which heterozygous diploid pools are transformed with the query and haploids are selected before microarray analysis (54) .
The application of SGA has also been extended from the simple combination of mutant alleles (deletions or conditional mutants) to plasmid-based assays, looking at how overexpression of genes affects viability in certain mutant backgrounds. Overexpression of a given gene can either rescue viability in a mutant background (multicopy suppression) or additionally compromise cell growth (dosage lethality). Dosage lethality screening takes advantage of a collection of 5800 cloned yeast genes, driven by the GAL1 promoter, which was originally generated for the production of protein arrays (55) . Recently, a comprehensive approach used SL and synthetic dosage lethality (SDL) to identify genes that are involved in chromosome segregation (44) . Whereas both the SL and SDL screens identified genes with functions in chromosome maintenance, they were nonoverlapping for many individual genes. This can be explained by distinct effects on cellular pathways associated with loss of function (deletion) and gain of function (gene overexpression). Besides known chromosome segregation factors, the SDL and SL screens also uncovered the iron transcription factor Rcs1p as a new component of the chromosomal segregation machinery. Very recently, gene dosage phenotypes were systematically analyzed in 5280 yeast strains overexpressing individual genes (56) . Approximately 15% of yeast genes conferred toxicity in the wildtype background when overexpressed. Furthermore, gene overexpression in the absence of the cyclin-dependent kinase Pho85p revealed targets for phosphorylation by Pho85p, among them the yeast calcineurin-responsive transcription factor Crz1p.
The principles of SGA analysis can also be extended and combined with other approaches. Drug sensitivities can be viewed as a form of synthetic genetic interactions (chemical genetic interactions) ( Figure 3C) . Charlie Boone and coworkers demonstrated how results from drug sensitivity and SL screens can be combined in chemical-genetic interaction profiles (21) . Ideally, in such a chemicalgenetic profile, deletion strains that are sensitive to a particular compound are also synthetically lethal or sick with a mutation in the compound's target gene. However, since the effects of most drugs are pleiotropic and the inactivation of a target by a drug is not completely equivalent to a gene deletion, the genetic interaction profile of a specific drug is typically not completely overlapping with the interaction profile of the drug target gene. Indeed, the same study demonstrated similar but not identical interactions for benomyl and its target TUB2, for fluconazole and its target ERG11, and also for FK506, cyclosporine, and their target calcineurinB (21) .
In the future, the SGA methodology will also be used to obtain information in addition to growth phenotypes and to integrate those into the yeast interaction network. So far, viable double mutants, generated in SGA screens, have been analyzed for growth and then discarded. However, it would be desirable to keep these strains as a valuable resource for further followup studies. A more recent effort aims now at the characterization of cellular morphologies of double and single mutants (C. Boone, personal communication). Looking beyond yeast, some of the principles for synthetic lethal screens by SGA can also be adapted for higher eukaryotes. Systematic screens using gene silencing by RNAi have been performed in the worm C. elegans (36, 57, 58) . This method can be easily adapted for synthetic lethal screens by simultaneously administering two different RNAi species.
GENOME-WIDE ANALYSIS OF PROTEIN LOCALIZATION
One aspect that is critical for the understanding of protein function is protein localization within distinct subcellular compartments and microenvironments. A first large-scale localization study in S. cerevisiae determined the subcellular localization of 2744 yeast proteins (59) . This study relied on transposon-mediated random tagging with hemaglutinin (HA) and paramyxovirus SV5 epitopes and overexpression of the tagged proteins. Although this work was very successful in showing the subcellular localization of a large amount of protein, errors may be introduced by the strategy of random tag insertion or by protein overexpression interfering with localization signals. Furthermore, the immunostaining procedure required fixation and processing of the cells. Therefore, a very important improvement toward a systematic localization of proteins constituted the use of light microscopy along with genetically encoded fluorescent proteins that allowed the visualization of protein trafficking and localization in vivo. In a large-scale localization study using green fluorescent protein (GFP) that was preformed by the O'Shea and Weissman laboratories, a GFP tag was inserted at the C terminus of 6029 yeast ORFs (60) . The results of these studies are accessible at yeastgfp.ucsf. edu. Out of this collection, 4156 strains expressed the GFP-tagged protein at detectable levels, and therefore 75% of the yeast proteome was covered. The GFP-tagged proteins were assigned to 23 localization categories that are refined for subcellular compartments and organelles (e.g., cytoskeleton, nucleolus, nuclear membrane, etc.). The comparison of data published by Huh et al. (60) with those from earlier localization studies revealed an agreement of 80%, supporting the reliability of the data. A potential source of error is introduced by the C-terminal fusion of the GFP protein, which may cause mislocalization through steric hindrance or interruption of C-terminal localization/retention signals. An additional, more recent, study by Kohlwein and colleagues investigated the localization pattern of proteins involved in lipid metabolism in S. cerevisiae by GFP tagging and high-resolution confocal laser-scanning microscopy (61). Enzyme localization patterns for phospholipids, sterol, and sphingolipid biosynthetic pathways indicated concerted regulation of sterol and sphingolipid metabolism in the endoplasmic reticulum, lipid droplets, vesicles, and the Golgi apparatus.
An important method to complement and to verify GFP localization data are enrichment or isolation of cellular organelles and subsequent identification of proteins by mass spectrometry. For example, from the 16 components of the spindle pole body that were identified by mass spectrometry (MS) (62), 14 were visible by GFP and localized to the spindle pole (60) . Similarly, GFP localization to the nuclear membrane was also confirmed for most of the proteins that were found in the purified nuclear pore complex (63) . The GFP localization information can be combined with data from other large-scale studies to confirm and extend predictions about protein functions. For example, proteins with a common localization that are also grouped together by genetic or physical interactions are very likely to have a common function. These predictions are especially useful in the case of proteins for which little functional data exist. In the future, a possible extension of the GFP localization studies could be the introduction of GFP fusion proteins into the deletion collection using highthroughput strain construction by SGA. Effects of individual gene deletions on protein localization can then be analyzed, allowing a genetic dissection of complex protein localization patterns within the cell.
YEAST INTERACTOME ANALYSIS BY TAP-TAGGING AND MASS SPECTROMETRY
A major focus for functional proteomics today is the analysis of physical interactions between proteins and the organization of the cellular proteome into multiprotein complexes. Biochemical isolation of these complexes, followed by identification of their individual components, is highly predictive for functional associations among proteins. By the analysis of molecular environments, new insights can also be obtained for proteins with an already known function. Thus, one of the major advancements in functional proteomics today is the systematic isolation of protein complexes followed by the identification of their components by mass spectrometry. Ideally, a method for large-scale protein purifications must be highly discriminating against nonspecific protein background but retain the specific components of the complex. Furthermore, the method should be generic to deliver reproducible and comparable results. The feasibility of high-throughput protein interaction studies depends therefore on protein tags that can be recognized by specific antibodies or by other high-affinity interactors. In 2002, two interactive proteomics papers were published that generated extensive protein-protein interaction networks (64, 65) . The Tyers group used a onestep purification procedure using the FLAG ® epitope tag as their method of REVIEW choice (64) . Bait proteins (725) were screened, among them a large number of protein kinases, phosphatases, and proteins implicated in DNA damage response. In total, 3617 protein interactions were observed with 493 baits. The overexpression of the FLAG-tagged protein is a potential advantage for the detection of a large number of interaction partners, but on the other hand, may also result in a higher amount of nonspecific interactions.
The TAP method allows purification of protein complexes under largely physiological conditions (66-68) (Figure 4 ). This methodology is highly discriminating against nonspecific protein background, because it relies on the utilization of two tags instead of one. Furthermore, the TAP-tagged protein is expressed from its normal chromosomal locus, and therefore, possible artifacts by protein overexpression are avoided. The tagged protein is isolated along with associated proteins or protein complexes by sequential purification over two high-affinity columns (Figure 4 ). In the first column, the proteinA moiety of the TAP-tag binds to immobilized immunoglobulins. After release from the column by protease cleavage using the tobacco etch virus (TEV) protease, the complex is bound to calmodulin-coated beads via the calmodulin binding peptide (CBP) tag. The removal of calcium ions with EGTA elutes the purified protein complexes. The proteins are then separated by gel electrophoresis and identified by matrixassisted laser desorption/ionization time-of-flight MS (MALDI-TOF MS). This TAP/MS-based approach is also readily applicable for the retrieval of protein complexes from human cell lines (65, 69) .
The described purification scheme was successfully used by the biotech company Cellzome (Heidelberg, Germany) in an initial large-scale proteomic study in which 589 tagged proteins were purified from S. cerevisiae (65) . Seventy-eight percent of the purified proteins were found with associated partners forming 232 multiprotein complexes. Very recently, Gavin et al. published a follow-up on the TAP approach that covered the entire yeast proteome with all ORFs tagged. In total, 1993 TAP-fusion proteins were purified, and 88% of these were identified with at least one partner (68) . One major concern is how the TAP-tag may interfere with complex assembly and protein function or localization. Indeed, for the first study, in 18% of the cases when essential genes were tagged at their C terminus, no viable strains were obtained (65) . An example for interference with complex assembly was observed for the CCT (chaperonincontaining tailless complex polypeptide 1) complex where the C termini of the eight subunits lie on the interaction surfaces in the ring-like core (68) . This loss of function may be circumvented by tagging at the N terminus. Despite these pitfalls, isolation of multiprotein complexes by TAP-tag has become a standard method to show biochemical interactions in yeast. In an independent study, the Weissman and O'Shea groups fused all ORFs in the yeast genome with C-terminal TAP-tags and assessed the expression level of each individual In a first purification step, the fusion proteins bind to immunoglobulin G (IgG) beads by their protein A domain. Cleavage by the TEV protease then releases the fusion proteins and the associated proteins or protein complexes from the IgG beads. In a second purification step, the fusion proteins bind to calmodulin-coated beads by their CBP domain in the presence of Ca 2+ . After additional washing, the tagged proteins are eluted by the addition of the chelator EGTA that binds to Ca 2+ . Purified protein complexes are then separated by denaturing gel electrophoresis. Distinct protein bands are excised and digested into small peptides with trypsin. The peptides are then identified by mass spectrometry, and the identity of the proteins is determined by database searches. m/z, mass-to-charge ratio; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis. tagged protein (70) . Abundance ranged from fewer than 50 to more than 10 6 molecules per cell, and 80% of the yeast proteome was expressed under normal growth conditions. This collection was used to direct another large-scale approach that involves the systematic purification of all yeast proteins and the subsequent identification of complex components by MALDI-TOF or liquid chromatography followed by tandem MS (LC-MS/MS) (71) .
Although a large number of protein complexes have been identified using the TAP-tag, there is still a considerable potential to improve the analysis of the yeast proteome. Being very discriminative in excluding nonspecific protein binding, the TAP-purification method may fail to detect transient interactions or low stoichiometry complex members. Furthermore, for TAP purifications followed by MS, a considerable volume of cells is used, and the preparation process is very labor-intensive. This is a disadvantage, especially when large numbers of protein-protein interactions have to be studied under a variety of environmental conditions. Hence, it would be a great advancement if protein-protein interactions could be assessed in a massive parallel approach, comparable to large-scale genetic and two-hybrid methods. Ideally, such a method would rely on a directed coimmunoprecipitation (co-IP) of differently tagged proteins, which allows a small sample size for cell growth and processing. Finally, co-IP could also be performed under less stringent conditions to favor the detection of transient and weak interactions. Nevertheless, some proteins will remain relatively inaccessible for biochemical isolation or refractory to tagging. These include membrane protein complexes that are difficult to analyze biochemically but often constitute important drug targets. Recently, the TAP-tag protocol was adapted for the identification of membrane protein complexes. This allowed retrieval of 340 of 628 TAP-tagged membrane proteins (68) . Although several membrane-protein complexes were identified this way, including the Q/t-SNARE complex, alternative methods are still required to get a better insight into membraneassociated complexes. To identify protein interaction partners of membrane proteins, a two-hybrid-based screening method has been developed to monitor these interactions indirectly (see the section on membrane two-hybrid screens). Undoubtedly, additional approaches are required to improve our understanding of protein-protein interactions and to cover the entire complexity of the yeast proteome.
PROTEIN MICROARRAYS AND APPLICATION ON YEAST PROTEINS
The protein microarray technology is an important development for high-throughput analysis of entire proteomes and is expected to transform biochemical analysis procedures in the future. Protein microarrays are generally of two types: analytical (or affinity) arrays and functional protein arrays. Analytical arrays contain antibodies, or other relevant protein binding entities, and are very useful for monitoring protein expression levels and for clinical diagnostics (72) . For functional protein microarrays, a set of proteins is deposited onto the surface of a slide under nondenaturing conditions and characterized using a wide range of biochemical assays. Binding assays for the immobilized proteins can be carried out using either a biotinylated probe, which can be detected by fluorescencelabeled streptavidin, or a probe that has been labeled directly with fluorescence. Functional protein arrays that cover a whole proteome can detect binding of a variety of labeled substrates, including protein ligands, lipids, small molecules, and DNA (see Figure 5 ) (reviewed in Reference 73) .
MacBeath and Schreiber first demonstrated the feasibility of protein microarrays in screening for proteinprotein interactions and in identifying the substrates of protein kinases and the protein targets of small molecules (74) . Important work by the Snyder laboratory highlighted the potential of protein arrays for large-scale biochemical analysis in yeast. The overexpression of 5800 ORFs tagged with glutathione S-transferase (GST)-fusion protein allowed the construction of the first full-scale proteome microarray (55) . The GST-fusions were purified in a high-throughput protocol, and detectable proteins were printed onto slides to form a yeast proteome microarray. The experiment then identified 6 known and 33 putative new binding partners for calmodulin 
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and a number of proteins that interacted with the lipid phosphoinositide. Recently, the yeast proteome microarray technology was used to determine the substrate specificities of 87 different yeast kinases (75) . The tested kinases phosphorylated 1325 different protein targets in a total of approximately 4200 phosphorylation events. The study found that distinct sets of substrates were phosphorylated by each kinase and that most substrates were only phosphorylated by a small number of kinases, indicating a strong preference of individual kinases for their respective targets. The authors confirmed that the phosphorylation status of a number of proteins, for which kinases were identified by this in vitro approach, indeed depended on the presence of the respective kinases in vivo. In another paper, the Snyder group demonstrated that comprehensive proteome arrays are suitable to examine antibody specificities (76) . Protein arrays were used to probe the yeast proteome with 14 different commercial antibodies that identified the correct cognate proteins but also showed antibody cross-reactivity with other yeast proteins. Proteome arrays have also been probed for DNA binding activities with fluorescent-labeled yeast genomic DNA (77) . In total, 200 proteins were identified, half of which were not known to bind DNA previously. Surprisingly, a DNA binding activity was discovered for a metabolic enzyme, Arg5,6p, which is involved in ornithine biosynthesis (a precursor to arginine). It seems very likely that such unbiased proteomic approaches using proteome arrays will also uncover unexpected new functions for other eukaryotic proteins in the future.
Perhaps the most important application of the proteome microarray technology is the screening for small molecule targets. The binding of bioactive compounds to individual proteins on the array can identify drug specificities, but also highlight potential side effects. One important study exemplifies how proteome chips can be used to identify compounds that modify the cellular signaling in response to the anticancer drug rapamycin (78) . Rapamycin specifically targets the TOR kinases that regulate cell growth in response to nutrient signals (12, 79) . First, a chemical suppressor screen was used to screen for compounds that enhance or inhibit the effect of the anticancer drug rapamycin on yeast cell growth. Biotinylated forms of the molecules that were found to completely suppress the effect of rapamycin in the screen were then used to probe yeast proteome arrays for direct interactions. Putative target proteins identified by this way included Tep1p, a homolog of the mammalian tumor suppressor PTEN, and Nir1p, which is a new component of the TOR signaling network. This study provides an example of how the combination of chemical genetics with proteome arrays could uncover potential new drug targets. Another possible strategy to assess drug target specificity could consist, for example, of a combination of yeast proteome array and haploinsufficiency screens. Hence, yeast proteome arrays can be used to discover potential new drug targets but also to validate targets that have been discovered by other approaches. Right now, development of commercially available proteome arrays is still in its infancy, and important technical issues remain unresolved. However, given the versatility of this approach in addressing molecule binding specificities and other functional aspects of entire proteomes, a major role for this technology in drug development can be expected in the near future.
YEAST TWO-HYBRID SYSTEM
Originally devised by Fields and Song, the yeast two-hybrid system uses transcriptional machinery of S. cerevisiae as a screening tool to discover novel protein interactions (80) . In the original implementation of the yeast two-hybrid system, a known protein of interest, the bait, is expressed as a fusion to a DNA binding domain of GAL4 (Figure 6A) , and an interacting protein, the prey, is expressed as a fusion to the GAL4 transactivation domain ( Figure 6B ). When expressed on its own, neither the bait nor the prey activates the reporter genes integrated into the yeast genome. However, when bait and prey are co-expressed, their interaction reconstitutes a functional transcription factor that is situated upstream of the reporter genes. This two-hybrid transcription factor activates the reporter genes, whose output is measured, for instance, as growth of yeast clones on selective medium or as blue coloration in a β-galactosidase assay ( Figure 6C ). 
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Traditionally, the yeast two-hybrid system has been used by researchers to tackle a single protein of interest (see Reference 81 for an in-depth description of a typical yeast two-hybrid screen). Novel potential interactors resulting from the screen are then confirmed by independent methods, such as in vitro pull-down assays or co-immunoprecipitation. Confirmation of interactions found in the yeast two-hybrid system is needed, since overexpression of foreign proteins in yeast often yields spurious, nonspecific interactions (so-called false positives) (see Reference 82 for a review on false positives in the yeast two-hybrid system). Once the candidate interactions have been confirmed, most researchers then move on to investigate the functional significance of these interactions in a biological model system. Eventually, they may come back to carry out another yeast twohybrid screen, for example by using one of the interactors found in the original screen as a bait. Albeit being a slow affair, this low-throughput screening has yielded invaluable information on protein interactions over the past decade. In fact, over 50% of all interactions published in Medline are derived from yeast two-hybrid screens (83) .
Attention has recently shifted toward trying to determine protein interactions on a large scale. These studies, termed high-throughput screens or interaction maps do not focus on a single protein of interest, but instead try to use available genome information to create a set of baits encompassing the entire expressed genome of an organism. As this approach deals with hundreds or even thousands of baits and preys, some form of automation is needed. Luckily, the yeast two-hybrid system is very amenable to robotic platforms, and several schemes have been developed to automate a yeast two-hybrid screen from cloning down to analysis of the interactors (84) . Initial attempts at creating genome-wide protein interaction maps focused on organisms with relatively few genes, such as viruses (85, 86) and prokaryotic species (87) . The first real attempt at mapping the complete interactome of a eukaryote was carried out for S. cerevisiae. Two independent groups created sets of baits and preys from the majority of the 6000 predicted genes of S. cerevisiae and used these in exhaustive large-scale screens (84, 88) .
What became rapidly apparent when analyzing the two high-throughput studies carried out for yeast was that the generated interactomes were far from complete. Analysis of the yeast interaction networks suggests that on average, every protein interacts with at least 2-3 partners. Assuming that the 6466 ORFs in yeast give rise to an equal number of proteins (which is a conservative estimate, since it does not take into account additional diversity through posttranslational modifications), one would expect to have at least 12,000-18,000 possible protein interactions in yeast. The considerably lower number of interactions found in the two systematic large-scale screenings carried out to date suggests that the false negative rate (i.e., a protein interaction that is undetectable in a yeast two-hybrid assay) is rather high. This is also obvious when looking at the overlap between large-scale screens carried out using the same organism. Comparison of yeast interaction data derived from the Uetz and Ito publications shows that only 20% of all protein interactions are found in both data sets, suggesting that both screens were far from saturating or contained false positives (84, 88) .
The recent large-scale screens carried out with the metazoan organisms D. melanogaster, C. elegans, Homo sapiens, and Plasmodium falciparum (89) (90) (91) (92) (93) (94) are likely to face even greater challenges when trying to cover the entire interactome, since extensive alternative splicing and posttranslational modifications massively increase (95) . Table 1 presents a selection of some large-scale yeast two-hybrid studies carried out to date.
Yeast Two-Hybrid System in Drug Discovery
As can be expected from a system that is so powerful for characterizing protein interactions in a natural setting, the yeast two-hybrid system has also been applied to the arduous task of drug discovery. In one adaptation, which has been termed small molecule three-hybrid, the two-hybrid system is modified to detect small moleculeprotein interactions instead of proteinprotein interactions. To achieve this, a bait is constructed by fusing the DNA binding domain to a protein with an affinity for a defined small molecule ( Figure 7A ). For example, dihydrofolate reductase (DHFR) binds the small molecule methotrexate. In a second step, the compound under investigation is chemically coupled to methotrexate, creating a hybrid molecule. When added to yeast expressing the DNA binding domain-DHFR bait, the methotrexate hybrid compound binds to the bait ( Figure 7B ). In the final step, the yeast is transformed with a cDNA library encoding activation domain fusions, and those proteins that bind to the displayed hybrid molecule are selected ( Figure  7C ). Several different versions of this small molecule three-hybrid approach exist and have been shown to work in proof-of-concept studies (96) , as well as for screening for binding partners of a given compound (97) . Perhaps the most interesting application to date has been its use in assaying the specificity of cyclin-dependent kinase inhibitors (96) . Overall, this type of approach shows great promise in characterizing the specificity of therapeutically relevant compounds in an in vivo like setting.
As a genetic selection assay for protein-protein interactions, the yeast two-hybrid system can also be manipulated to screen for inhibitors of a protein-protein interaction. Here, the selection mechanism is reversed, such that the interaction between a bait and its cognate prey leads to activation of a toxic reporter gene, which then kills the yeast when grown on a special selective medium ( Figure 8A ). The addition of a compound, which inhibits the protein interaction, prevents expression of the toxic gene and restores yeast growth on the selective medium ( Figure 8B ). The most commonly used reporter gene is URA3, which converts the compound 5-fluoroorotic acid (5FOA) into a toxic metabolite, resulting in growth arrest and cell death (98) . Thus, a collection of small molecules can be screened to identify those candidates that inhibit a given protein interaction. This reverse yeast two-hybrid system has been adapted to a high-throughput format and has been used to demonstrate the disruption of activin receptor R1 binding to the immunophilin FKBP12 by the small molecule FK506 (99) . An alternative approach to screening using the yeast two-hybrid system was used by Khazak and coworkers; here, disruption of a protein-protein interaction by small molecules is detected by measuring the output of two colorimetric reporter genes. Using the interaction between Ras and Raf-1, the authors identified a compound which, when tested in cell culture, was able to cause reversion of ras-transformed phenotypes including morphology, in vitro invasiveness, and anchorageindependent growth (100).
Tackling More Complex Problems: Modification-Dependent and Compartment-Dependent Protein Interactions
In the past decade, it has been demonstrated that the yeast two-hybrid system can tackle a surprisingly broad range of different protein interactions (101) . However, it has also become clear that certain classes of proteins and protein interactions are outside of the scope of yeast two-hybrid. Unfortunately, precisely those protein interactions become increasingly important when one moves toward establishing protein interaction maps of higher eukaryotes such as mouse or human or when trying to take advantage of protein interactions as novel avenues in drug discovery. For example, yeast has a much more limited repertoire of posttranslational modifications than higher eukaryotes, such as C. elegans or humans. Therefore, many protein interactions that are dependent on such modifications will be undetectable in a yeast two-hybrid screen since yeast lacks the necessary 
A B
machinery to modify the exogenously expressed bait or prey proteins. A possible solution to this problem is to co-express the modifying enzyme along with its substrate. Fields and collaborators have recently presented a tethered catalysis two-hybrid system, which they successfully used to map interactions dependent on phosphorylation and acetylation. In this approach, constitutive modification of the bait is achieved by its fusion to a cognate modifying enzyme, for example a kinase or an acetylase. The fusion of substrate and enzyme results in efficient catalysis and ensures that the majority of the bait is posttranslationally modified. To demonstrate the general usefulness of the approach, the authors identified yeast proteins that interact with acetylated histones and proteins that specifically interact with the phosphorylated C-terminal tail of RNA polymerase II (102) . Further development of this system and its application to high-throughput interaction screening may eventually lead to the creation of a posttranslational modification-dependent interactome map.
Another limitation of yeast two-hybrid touches integral membrane proteins. In the yeast two-hybrid system, both the bait and the prey have to be localized in the nucleus to ensure detection of the interaction. Integral membrane proteins cannot be used as baits or preys since they would be immediately translocated to the membrane during translation and therefore would not be able to reach the nucleus. Thus, most interactions involving integral membrane proteins will be undetectable by yeast two-hybrid. In recent years, novel screening assays, based on the yeast two-hybrid system, were generated that aim at the detection of protein interactions outside of the nucleus. These approaches include among others the son of sevenless (SOS) recruitment system (103), an interaction assay based on RNA polymerase III activation (104) , the use of G protein fusions (105) , and a system based on the unfolded protein response (106) . Here, we will focus on the reverse Ras (rRas) system (107) and the split-ubiquitin membrane-based yeast two-hybrid system (MbYTH system), since they have seen the widest application to date.
The rRas system, developed by Aronheim and colleagues (108) , uses the Ras pathway in yeast as a selection mechanism. When localized at the plasma membrane, the yeast Ras guanyl exchange factor cdc25 stimulates guanyl nucleotide exchange on Ras and promotes downstream signaling events that ultimately lead to cell growth (108) . A mutant yeast strain carrying the temperature-sensitive cdc25-2 allele is able to grow at the permissive temperature of 25°C, but fails to grow when shifted to 36°C ( Figure 9A ). The rRas system exploits this deficiency to identify protein interactions at the membrane. An integral membrane protein (the bait) is expressed and targeted to the membrane ( Figure 9A ). An interacting protein (the prey) is expressed as a fusion to a constitutively active Ras mutant (mRas). Upon the interaction of bait and prey, mRas is translocated to the membrane, where it takes over the function of the defective cdc25 protein. Consequently, yeast harboring a protein interaction is able to grow at the nonpermissive temperature of 36°C ( Figure 9B) . Recently, the Ras system has been used to isolate interactors of small GTPases (109) and to develop a cellular screening assay for receptor tyrosine kinases (110) .
The MbYTH system, developed by our group (111) , is an adaptation of the split-ubiquitin protein complementation assay (112) . An integral membrane protein of interest (the bait) is fused to the C-terminal half of yeast ubiquitin (termed Cub), followed by a transcription factor composed of the Escherichia coli LexA protein and the VP16 transactivator derived from the herpes simplex virus. When no protein interaction takes place, the transcription factor is immobilized at the membrane and is unable to reach the nucleus ( Figure 10A ). An interacting protein (which can be an integral membrane protein or a cytosolic protein, the prey) is fused to the corresponding N-terminal half of ubiquitin (termed NubG). If bait and prey interact, the proximity of the Cub and NubG modules forces their association to form split-ubiquitin. The split-ubiquitin is recognized by ubiquitin-specific proteases (UBPs) present in the yeast cytosol. The UBPs cleave the polypeptide chain Cterminal to Cub, releasing the attached transcription factor, which then translocates to the nucleus and activates its cognate reporter genes ( Figure 10B) .
The immediate advantage of the MbYTH system is the separation between protein interaction and the subsequent detection through a transcriptional output. For this reason, the system is suitable for assaying protein interactions that take place outside of the nucleus, for example at the plasma membrane (113) . There is now a number of reports showing that the MbYTH system is capable of detecting interactions involving all types of integral membrane proteins REVIEW and membrane-associated proteins (114) (115) (116) , and it has also been used successfully to find novel interactors by cDNA library screening (117) (118) (119) . In addition, the MbYTH system has recently been used on the large scale to identify interactions between S. cerevisiae integral membrane proteins. Among 705 selected integral membrane proteins, 1985 putative interactions involving 536 proteins were identified. The results identified potential new components of established biological processes and novel roles for integral membrane proteins of ascribed functions (120) . As the detection of a protein interaction in the MbYTH system relies on the same transcriptional mechanism as the yeast two-hybrid system, its adaptation to drug screening purposes should be easily possible by converting the abovementioned systems. The added advantage is that with the MbYTH system, full-length integral membrane proteins, which represent the majority of today's drug targets, suddenly become accessible to screening. While it is well suited to integral membrane proteins, a drawback of the MbYTH system is that it cannot be used with cytosolic proteins as baits, since translocation of the soluble bait to the nucleus would activate the reporter genes in the absence of a protein interaction. This shortcoming can be prevented by attaching a cytosolic protein to the membrane by means of an additional membrane anchor (N. Möckli and D. Auerbach, unpublished) . A different screening system based on the split-ubiquitin system has been developed by Johnsson and coworkers (121, 122) . Here, the protein attached to the C terminus of Cub consists of the yeast Ura3p protein.
In the absence of a protein interaction, the Ura3p located on the cytosolic face of the membrane converts the compound 5FOA into a toxic metabolite, poisoning the yeast. Upon interactions with a NubG-fused prey and assembly of split-ubiquitin, the Ura3p is cleaved off, exposing a destabilizing N-terminal residue. Consequently, the destabilized Ura3p is rapidly degraded by the 26S proteasome, and yeast harboring the protein interaction is able to grow in the presence of 5FOA in the medium. When compared with the MbYTH system, the Ura3p-based system does not require attachment of the bait to the membrane, and it can therefore be used with cytosolic and even nuclear proteins (123) . The option to screen nuclear proteins, such as transcription factors, presents another example of how newly developed technologies are overcoming disadvantages of the original yeast two-hybrid system.
CONCLUSIONS AND FUTURE DIRECTIONS
Functional genomics and proteomics are emerging subdisciplines of Systems Biology expected to have a major impact on the future of biological and medical research. In order to fulfill this daunting task, the scientific community requires reliable model systems in which detailed studies can be performed accurately, rapidly, and reproducibly. Ever since Leland Hartwell and Paul Nurse set out to investigate the cell cycle using yeast as a model system, this simple fungus has seen a remarkable number of different applications, culminating in todays systems biology approaches that aim at describing cellular features such as gene expression, protein abundance, localization, and proteinprotein interactions at a genome-wide scale. Why has yeast been so hugely successful as a model organism? The answer probably lies in the unique combination of several features such as its genetic tractability, ease of manipulation, and the fact that many genes are highly conserved between yeast and human. Moreover, another important reason why yeast is a popular model organism lies in the unique yeast research community, which is well organized, open for exchange of data and materials, and has a demonstrated record in many joint achievements such as the sequencing of yeast genome, systematic knockout studies, synthetic genetic arrays, knock-in fusions of ORFs with GFP and TAP tags, and genome-wide micoarray studies. All these large-scale studies have yielded a wealth of data on yeast gene function and have provided important insights into how the approximately 6400 genes of yeast are making this unicellular eukaryote. Currently, most of this data are still deposited in single and largely unconnected databases. The future progress of functional genomics and proteomics using the budding yeast as a model system will involve refinement of current databases and the integration of data sets from different yeast-based systems biology studies. For example, data derived from largescale protein interaction studies can be combined with data from genetic interaction networks and transcriptome data to improve the general quality of the data set. To make the most out of the available data, it will be crucial to develop standards for recording data obtained by large-scale experiments Figure 10 . The membrane yeast two-hybrid (MbYTH) system. (A) A bait is constructed by expressing an integral membrane protein or a membrane-associated protein X as a fusion to the C-terminal half of ubiquitin (C), followed by a transcription factor (L). Fusion of the transcription factor to the integral membrane protein prevents its translocation to the nucleus and activation of the reporter genes. A prey is constructed by expressing an interacting protein Y as a fusion to the N-terminal half of ubiquitin (N). (B) If bait and prey interact, the N-and C-terminal halves of ubiquitin are forced into very close proximity and reassociate to form split-ubiquitin, which is recognized and cleaved by ubiquitin-specific proteases (UBP) in the cytosol. The cleavage liberates the transcription factor from the membrane, followed by its translocation to the nucleus and activation of reporter genes.
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and to integrate existing and new data for better access. Another important future goal of the yeast research community will be to express and purify each yeast protein as well as to generate a collection of yeast strains in which each ORF is endogenously tagged with different short tags that can be recognized by commercially available antibodies. Very recently, the Grayhack and Snyder groups did an important step toward this goal by generating a versatile expression library that contains 5854 ORFs Cterminally tagged with 6×His and HA epitopes (124) . In addition, they have demonstrated the effectiveness of this expression library to perform the first systematic survey of glycosylated proteins in yeast.
Clearly, these new developments will be highly instructive in understanding the molecular function of the remaining approximately 2000 yeast ORFs whose function is not yet known. Toward this end, the yeast S. cerevisiae will continue to have a key role as an important model organism in the development of many current and future functional genomics and proteomics technologies.
